DEF: Glaukos Sets 2026 Annual Meeting Date, Proposes Director Nominees

Glaukos Corporation announced its 2026 Annual Meeting of Stockholders, scheduled for May 28, 2026, and outlined key proposals including director elections and executive compensation.

Summary

• Glaukos Corporation is holding its 2026 Annual Meeting of Stockholders on Thursday, May 28, 2026, at 9:00 a.m. Pacific Time.
• The meeting will be conducted virtually via a live audio webcast.
• Key items of business include the election of two Class II directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
• The company's mission is to transform vision by pioneering novel, dropless platforms for sight-threatening chronic eye diseases.
• As of December 31, 2025, Glaukos reported $507 million in net sales and had $283 million in cash, equivalents, restricted cash, and short-term investments, with no debt.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial performance, successful product launches, and a clear strategic outlook, despite acknowledging some market access challenges.

Positives

• Achieved total net sales growth of 32% in fiscal year 2025 compared to fiscal year 2024.
• U.S. Glaucoma net sales grew by 50% in fiscal year 2025 versus fiscal year 2024, driven by iDose TR sales of approximately $136 million.
• International Glaucoma net sales grew by 18% in fiscal year 2025.
• Corneal Health net sales grew by 8% in fiscal year 2025.
• Received U.S. FDA approval for Epioxa in October 2025.
• Expanded non-GAAP gross margins to approximately 85% in the fourth quarter of fiscal year 2025.
• Ended 2025 with $283 million in cash and equivalents and no debt.
• Achieved 100% companywide completion of annual cybersecurity awareness training.
• Broke ground on a new R&D and manufacturing facility in Huntsville, Alabama.
• Increased 401(k) company match to $0.50 on the dollar up to the first 8% of an employee's contributions.
• Employees logged 870 volunteer hours and participated in 61 community service events.
• Provided over $22 million to date in product donations to help needy patients.

Negatives

• The company notes potential market access considerations and increasing competitive products and procedures facing its glaucoma business.
• The Medicare Administrative Contractor confirmed non-coverage for surgical MIGS procedures in combination with other surgical MIGS procedures, impacting US glaucoma sales.

Risks

• Ability to successfully commercialize iDose TR and Epioxa therapies.
• Impact of general economic conditions, foreign currency fluctuations, and public health crises.
• Supply and/or manufacturing disruptions, including product recalls or serious safety issues.
• Ability to achieve or sustain profitability and develop and commercialize additional products.
• Risks associated with international operations.
• Ability to meet customer expectations for product quality or delivery.
• Potential for misuse of products.
• Ability to manage growth and meet customer demand.
• Success of acquisitions, collaborations, and partnerships.
• Ability to protect information systems against cyber threats and comply with data privacy laws.
• Risks related to the implementation of AI and machine learning technologies.
• Availability of net operating loss tax carryforwards.
• Risks related to capped call transactions.
• Changes to domestic or foreign healthcare laws or trade policies.
• High cost of regulatory compliance and participation in federal healthcare programs.
• Risks related to securing or maintaining adequate coverage or reimbursement.
• Lengthy and expensive clinical trial processes and uncertainty of outcomes.
• Expense and time-consuming nature of protecting intellectual property and impact of infringement claims.

Future Outlook

Glaukos is well-positioned to sustain strong growth momentum in 2026, driven by the continued advancement of iDose TR and the launch of Epioxa, opening new paradigms in interventional keratoconus and rare diseases. The company expects these opportunities to underpin a best-in-class growth profile well into the next decade, supported by continued investment in its pipeline and disciplined capital allocation.

Management Comments

• Our mission at Glaukos is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases.
• Innovation is at the core of everything we do. Our mantra Well Go First embodies our commitment and determination to take chances, push the limits of science, and disrupt the legacy treatment paradigms in glaucoma, corneal disorders, and retinal diseases through our pursuit of game-changing technologies.
• Our achievements in 2025 leave us excited about our prospects. As we enter into 2026, we are well positioned to sustain our strong growth momentum, led by two transformational growth drivers, including the continued advancement of the Interventional Glaucoma treatment paradigm with iDose TR, along with the launch of Epioxa, opening up a new paradigm in interventional keratoconus and rare diseases.
• The Company and the CNG Committee listen to the priorities of our stockholders, with the intention of responding to those priorities in an appropriate and thoughtful manner that considers the Companys stage in its development cycle and its needs from a leadership, financial and operational perspective.
• We believe that sustainability represents a path to long-term growth and value for all of our stakeholders.

Industry Context

StockSavvy.ai notes that Glaukos's focus on novel, dropless platforms for chronic eye diseases aligns with a broader industry trend towards less invasive and more patient-friendly treatments. The company's expansion into corneal disorders with Epioxa and continued development in glaucoma with iDose TR position it to capitalize on significant unmet needs in ophthalmology.

Corporate Governance

Related Party Transactions

• The son of the Chairman and CEO was employed by the company in 2025 with compensation of approximately $350,000.
• The daughter of the Chairman and CEO was employed by the company in 2025 with compensation of approximately $180,000.

Stakeholder Impact

• Shareholders: The company's growth strategy, product development, and financial performance are aimed at maximizing long-term shareholder value.
• Employees: The company offers competitive compensation, benefits, and development opportunities, with a focus on culture and engagement.
• Patients: The company's mission is to improve patient outcomes through innovative treatments for sight-threatening eye diseases, including product donations.
• Customers: The company aims to meet customer expectations for product quality and delivery.

Next Steps

• Elect two Class II directors at the Annual Meeting.
• Approve, on an advisory basis, the compensation of Named Executive Officers.
• Ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• Continue to advance the commercial launch of iDose TR and Epioxa.
• Continue to develop and advance the company's product pipeline.

Key Dates

Recommendation

Glaukos has demonstrated strong execution and growth, particularly with its key products iDose TR and Epioxa. The company's financial health is solid, with significant cash reserves and no debt. However, the filing also highlights market access challenges and competitive pressures in the glaucoma segment. While the outlook is positive, the current valuation and the need for continued execution on pipeline development and market penetration warrant a 'hold' recommendation, allowing investors to monitor progress and potential headwinds.

Keywords

Glaukos Corporation, Proxy Statement, Annual Meeting, Director Nominees, Executive Compensation, Audit, iDose TR, Epioxa, Glaucoma, Ophthalmology, Medical Technology, SEC Filing, DEF 14A